Bill Desmarais is Alchemab’s Chief Business Officer where he focuses on executing the company’s global business development and strategic transactions. Prior to joining Alchemab, Bill was Chief Business Officer at TScan Therapeutics, where he led a key discovery platform transaction with Amgen. Prior to joining TScan, Bill held senior business development roles at Momenta Pharmaceuticals […]

Becky is Alchemab’s Human Resources Director where she oversees all strategic and operational HR activity across the U.K. and U.S. Prior to Alchemab, Becky served as the European HR Director at Silence Therapeutics, where she managed all aspects of human resources for the U.K. and German entities. Prior to joining Silence Therapeutics, Becky held various […]

Alex Hewitson is our Senior Vice President of Operations and Chief of Staff, where he has global oversight of our operations footprint and our human resources function. Prior to joining Alchemab, Alex held several senior leadership roles within AstraZeneca where he was most recently Head of Operations, ensuring business operations were maintained during the company’s […]

Peter Catalano is our Head of Finance and oversees our finance, accounting, and treasury functions.  Prior to joining Alchemab, Peter served as the Senior Finance Manager – Immunology at Janssen Pharmaceuticals Companies of Johnson & Johnson, where he managed the Immunology R&D portfolio and the integration of the Momenta Pharmaceuticals finance and accounting functions following […]

Young Kwon is Alchemab’s Chief Executive Officer and provides overall leadership to the company. Prior to joining Alchemab, Young held various leadership roles as a senior executive at Momenta Pharmaceuticals, most recently as Chief Financial and Business Officer, where he was responsible for business development, strategy, finance, investor relations, and commercial. During his tenure at […]

Paul Varley is our Senior Vice President of Development where he oversees our development processes including Pre-clinical Development, Toxicology, Chemistry Manufacturing and Control (CMC) and Quality. Prior to joining Alchemab, Paul held similar roles at Kymab, Ltd., AstraZeneca/MedImmune and Cambridge Antibody Technology. Paul also worked at British Biotech, the UK National Institute of Biological Standards […]

Olivia Cavlan is Alchemab’s Chief Corporate Development and Strategy Officer where she oversees global business development and partnerships and leads corporate strategy. Prior to Alchemab Olivia was an Investment Principal at SV Health Investors and a Partner with McKinsey & Company where she was part of the leadership team in the Healthcare Private Equity and […]

Jane Osbourn is Alchemab’s Chief Scientific Officer and oversees all aspects of our drug discovery activities. Prior to joining Alchemab, Jane served as Vice President of R&D at MedImmune, the biologics arm of AstraZeneca, where she contributed to the development of antibody phage display technology, authored key publications and patents and contributed to the discovery […]